“with the principal investigator attributing the death to septic shock from a perforated duodenal ulcer amid a complex clinical course that included acute liver injury treated with corticosteroids. Intellia reported that more than 650 patients with ATTR-CM and 47 patients with hereditary ATTR amyloidosis with polyneuropathy have been enrolled across the two trials, with Grade 4 liver enzyme elevations observed in less than 1% of MAGNITUDE participants and none in MAGNITUDE-2, and said it will update stakeholders once it has agreed with regulators on a path forward for nex-z, underscoring both the regulatory risk around its flagship ATTR program and the broader safety and development uncertainties facing first-in-class in vivo CRISPR therapies.”
Seems like a good update after the unfortunate death of a patient last November. Hopefully things will get back on track soon.
[https://www.tipranks.com/news/company-announcements/intellia-updates-investors-on-nex-z-trial-safety-hold](https://www.tipranks.com/news/company-announcements/intellia-updates-investors-on-nex-z-trial-safety-hold)